SPR has evolved into a core technology for drug discovery, delivering real-time, label-free kinetic and mechanistic insight. This brief article provides a high-level overview of how SPR works and how it is evolving to provide even more value to scientists. Read more: drughunter.com/articles/sur...

In September 2025, paltusotine (Palsonify®) became the first nonpeptide oral therapy to gain FDA approval for the treatment of acromegaly. Read more on Drug Hunter: drughunter.com/molecule/pal...

Elinzanetant is a dual NK1R/NK3R antagonist approved in October 2025 for the treatment of moderate to severe VMS due to menopause. Check out the full case study on Drug Hunter: drughunter.com/molecule/eli...

Patent Target Brief: Macrocycles Targeting the LAG3:MHC-II Protein–Protein Interactions | drughunter.com/articles/pat... Markush structures, representative examples, and biological data are shown in this Patent Target Brief. Read it on Drug Hunter: drughunter.com/articles/pat...

Repurposed Sheep Antiparasitic Monepantel (NUZ-001) Enters HEALEY-ALS Platform Trial An mTOR inhibitor that induces autophagy, Neurizon Therapeutics' NUZ-001, aims to enhance the clearance of aggregation-prone proteins, a hallmark of ALS. Read it on Drug Hunter: drughunters.com/3LAg9wD

Discovery of CHF6333: An Inhaled Neutrophil Elastase Inhibitor | lnkd.in/gKeQPiE6 This case study summarizes the discovery and optimization of CHF6333, as presented by Fabio Rancati at the RSC/SCI 23rd Medicinal Chemistry Symposium. Read it on Drug Hunter: lnkd.in/gKeQPiE6

Sepiapterin (Sephience®), an orally bioavailable PAH (phenylalanine hydroxylase) activator from PTC Therapeutics, was approved in July 2025 for the treatment of PKU (phenylketonuria), a condition characterized by neurotoxic Phe (phenylalanine) accumulation. Read more | drughunters.com/4qXq9Ak

drughunters.com/43lGuVj Starting January 2026, the Drug Hunter team will release bite-size, <30 minute recorded lectures that distill the modern biopharma industry and drug discovery to essential knowledge for scientists Sign Up for the Course Navigation Webinar on Dec 9th: drughunters.com/47wNwsR

Pfizer recently disclosed the discovery journey of PF-07293893, an oral, selective activator of AMPKγ3 developed for the treatment of HFpEF (heart failure with preserved ejection fraction). Read it on Drug Hunter: drughunter.com/molecule/pf-...

Darovasertib is a potential first-in-class, oral pan-PKC inhibitor with both Orphan Drug and Breakthrough Therapy designations and is one of the most clinically advanced targeted therapies for uveal melanoma. Read it on Drug Hunter: drughunter.com/molecule/dar...

Cracking the Entry Code: CD36 as a Key Receptor for Heterobifunctional Degrader Cellular Uptake CD36 has recently been identified by Wang et al. as a mediator of cellular uptake for heterobifunctional degraders and other beyond-rule-of-five (bRo5) molecules. Read more: drughunters.com/464k5MG

PF-07853578: Leveraging Chemical Biology to Target a Genetically Defined Driver of MASLD | PF-07853578 covalently binds to PNPLA3(I148M), displacing it from lipid droplets and promoting its degradation: a novel strategy to restore lipid metabolism. Read more: drughunter.com/molecule/pf-...

Big Money Bets from June 2025 | drughunters.com/44NDWzb In our June recap of biopharma deals, we highlight Sanofi acquiring Blueprint for $9.1B, Novo Nordisk partnering with Deep Apple Therapeutics on small molecule obesity drugs, and more! Read it on Drug Hunter: drughunters.com/44NDWzb

Can Brensocatib Open the Door for Neutrophil-Modulating Drugs? | drughunters.com/3ItDcb2 If approved, brensocatib would not only address a major unmet medical need but also serve as a template for rational neutrophil-targeting drug design. Read it on Drug Hunter: drughunters.com/3ItDcb2

BBO-10203, A Potential First-in-Class PI3Kα:RAS Protein-Protein Interaction Inhibitor Advances to Phase I Trials | drughunters.com/4ksBKTl Learn more about BBO-10203, including its discovery, binding mode and much more in our full Drug Hunter case study! Read more: drughunters.com/4ksBKTl

JNJ-6640 Reveals Purine Deprivation Strategy Against Drug-Resistant TB Read it on Drug Hunter: drughunters.com/3TwdLYr

IRF5 Target Review: Highlighting Two Divergent Approaches to an "Undruggable" Transcription Factor Read it on Drug Hunter | drughunters.com/4ktbY1l

Key Clinical Updates from April 2025 In our recap of April’s clinical updates, we highlight the accelerated approval of Novartis’ atrasentan for immunoglobulin A nephropathy and two oral GLP-1 receptor agonists that are ready to seek approval from the FDA. Read now | drughunters.com/3ZsymjF

Drug Hunter April 2025 Annotated Searchable Patent Table | drughunters.com/4mq3tGE This month’s collection features an exciting array of innovations, including antiviral agents, LRRK2 degraders, SARM1 inhibitors, CK1α degraders and more! Read it on Drug Hunter | drughunters.com/4mq3tGE

Pretzel recently announced initiation of recruitment for a Ph. I study for their undisclosed lead POLγ-targeting asset, PX578, which is likely similar to PZL-A based on their recent patent publications. Read it on Drug Hunter | drughunters.com/4mpQQeO

Bayer Discloses its Selective Dual Factor IIa/Xa Inhibitor, BAY 3389934 In this molecule profile, we highlight the key structural features behind the discovery of BAY 3389934 as a nanomolar-potent, highly soluble compound designed for i.v. administration. Read now | drughunters.com/4mimeeQ

Now in Ph. I trials for advanced solid tumors, RP-1664 represents a promising test of whether PLK4 inhibition can serve as a precision oncology strategy in TRIM37-amplified cancers such as breast adenocarcinoma and neuroblastoma. Read more: t.co/YV8luFWahY

Explore our bioisosteres cheat sheet. Check out how these bioisosteres impact drug properties, improve oral bioavailability, and reduce potential liabilities, ultimately shaping the success of modern therapeutics. Read more: drughunters.com/4mc2REq

In our recap of April biopharma deals, we highlight Nurix licensing a transcription-factor degrader to Sanofi, Prazer Therapeutics raising $20M for targeted protein degraders, and Merck KGaA buying SpringWorks for $3.9B. Read more: t.co/dvj6F2s4KD

BMS-986458 is an orally bioavailable CRBN-mediated heterobifunctional degrader of BCL6 currently in Ph. I/II clinical trials for relapsed/​refractory non-Hodgkin lymphomas. Read it on Drug Hunter | drughunters.com/3RWISvv

GSK and IDEAYA’s (S)-27 is a preclinical, covalent acrylamide inhibitor of WRN helicase—a validated synthetic lethality target in MSI-H tumors. Read more: drughunters.com/4k3Dvqi

A Fluorinated Macrobicyclic Antibiotic with Gram-Negative Activity | drughunters.com/43kiq5m BT-33 is a compelling example of how rigidification and conformational preorganization can revitalize legacy scaffolds for modern antibacterial challenges. Read more: drughunters.com/43kiq5m

Alumis’ lead candidate ESK-001 is a potential best-in-class allosteric TYK2 inhibitor for immune-mediated diseases like plaque psoriasis and SLE. Read more: drughunters.com/4iPPpDi

Currently in Ph. II/III trials for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, ALKS 2680 is helping to redefine the therapeutic landscape for sleep-wake disorders. Read more: drughunters.com/42FAtCP

New Drugs on the Horizon from #AACR2025! 12 clinical molecules, 12 fresh stories from the frontlines of drug discovery. The full article covers the science, mechanism of action, and clinical context behind each of these new drug compounds. Read more: t.co/h10fFwojvX